Abstract
The persistent challenge of developing effective treatments for Alzheimer's disease (AD) has led researchers to explore various therapeutic approaches. Among these, non-peptidic anti-aggregate compounds have emerged as particularly promising candidates due to their potential to prevent the formation of toxic amyloid aggregates while offering advantages in stability, bioavailability, reduced immunogenicity, and better pharmacokinetic properties over peptide-based alternatives. These compounds encompass diverse categories, including small molecules, metal chelators, molecular chaperones, and allosteric modulators, each with unique mechanisms to inhibit, disaggregate, or prevent the formation of amyloid-β (Aβ) and tau aggregates that cause neural disfunction. Although recent advancements in Alzheimer's research have highlighted the therapeutic potential of natural products such as rutin, curcumin, and resveratrol, along with synthetic agents like tramiprosate and innovative chemical chaperones, challenges such as ensuring specificity, minimizing off-target effects, and demonstrating long-term safety remain critical. This review therefore enumerates the current progress, mechanisms, and future prospects of non-peptidic anti-aggregate compounds, emphasizing their role in addressing the unmet clinical needs of AD therapy. The role of nanotechnology and artificial intelligence (AI)/machine learning (ML) in AD therapy is also briefly highlighted. With continued research and innovation, these compounds could pave the way for more effective and accessible treatments for this debilitating disease.